InvestorsHub Logo
icon url

rcstock

10/06/17 11:36 AM

#76002 RE: Triple9 #76001

Interesting ! Particularly with our meetings with JNJ component.
The company MUST have some diabetes lab test data they shared wih JNJ. Couple this with modified relation with Austranvo and we may have some real news in the near future.
icon url

tulla236a

10/06/17 12:30 PM

#76009 RE: Triple9 #76001

wow, thanks trip! it seems a little early to bail on that if the janssen deal is true. maybe it's not a good income producer now. or maybe fast track for ciab, excellent results on diabetes preclinical, buyout coming sooner than later???

1234, janssen is the canada thingy, speculation at this point. i seriously doubt that it will be confirmed by kw before ind approval if true.
icon url

tjclark0551

10/06/17 3:03 PM

#76013 RE: Triple9 #76001

Trip,

I saw that yesterday on my yahoo finance and had similar thoughts. You just don't know, we'll just have to wait and see.
icon url

north40000

10/06/17 3:37 PM

#76017 RE: Triple9 #76001

Animas had DXCM in its innards. A FIT and DXCM recent PR announced a collaboration to place DXCM blood glucose sensing technology within a new watch that FIT hopes to introduce in early 2018---wear on the wrist, see glucose values in bloodstream + rate of change of bg value.

Of further interest is FDA selection or listing of JNJ and FIT among a group of 9 companies to collaborate in developing a non-invasive bg sensing means. Another PR from JNJ today or recently seems to indicate its One Touch system to detect bg values is being phased out and a shift to a different system is in the works.

Meantime, are AAPL and GOOGL continuing with their attempts to develop a contact lens that will accurately sense bg values from eye fluids?

Interesting times in management of diabetes.
icon url

rudygerner

10/06/17 7:24 PM

#76027 RE: Triple9 #76001

Excellent dd.

Johnson & Johnson is coming for our diabetes treatment imo.

That would help explain the lack of diabetes updates.